0
     

Report Added
Report already added
Molecular Diagnostics Market by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2027

Molecular Diagnostics Market by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2027

The global molecular diagnostics market is projected to reach USD 30.2 billion by 2027 from USD 23.2 billion in 2022, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as the increasing use of PoC diagnostic tests, the rising funding for R&D in molecular diagnostics, the increasing prevalence of infectious diseases and cancer. On the other hand, an unfavorable reimbursement scenario and the high cost of instruments may restrain the growth of this market to a certain extent.

“The DNA sequencing & NGS segment accounted for the highest growth rate in the molecular diagnostics market, by technology, during the forecast period”

The molecular diagnostics market is segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), in situ hybridization (ISH), DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & NGS segment is expected to register the highest growth rate during the forecast period. Factors such as the growing focus of key market players on developing and launching diagnostic NGS kits and panels, increasing applications of sequencing in genomics research, and the increasing focus on molecular-targeted drugs/therapies (personalized medicine) contribute to the growth of this segment.

“Oncology testing segment accounted for the highest CAGR”

Based on applications, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The oncology testing segment is expected to register the highest CAGR during the forecast period. Technological advancements, the increasing prevalence of cancer, and the growing focus on personalized medicine contribute to the growth of this market segment.

“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”

The global molecular diagnostics market is segmented into five regions - North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to witness the highest growth in the molecular diagnostics market during the forecast period. This can be attributed to factors such as continuously rising healthcare expenditures, government efforts to increase awareness about the early detection of diseases and regular health check-ups, an increasing number of hospitals and clinical diagnostic laboratories in India and China, and strengthening research bases for diagnostic procedures across India, China, and Japan. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
•By Designation: C-level - 27%, D-level - 18%, and Others - 55%
•By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6% , and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
•F. Hoffmann-La Roche Ltd. (Switzerland)
•Hologic, Inc. (US)
•Thermo Fisher Scientific, Inc. (US)
•PerkinElmer, Inc. (US)
•Abbott Laboratories (US)
•bioMérieux SA (France)
•QIAGEN N.V. (Netherlands)
•Myriad Genetics, Inc. (US)
•Siemens Healthineers AG (Germany)
•Danaher Corporation (US)
•Illumina, Inc. (US)
•Becton, Dickinson and Company (US)
•Grifols, S.A. (Spain)
•Quidel Corporation (US)
•Agilent Technologies, Inc. (US)
•DiaSorin S.p.a. (Italy)
•Exact Sciences Corporation (US)
•Genetic Signatures (Australia)
•MDx Health (Belgium)
•Biocartis NV (Belgium)
•TBG Diagnostics Limited (Australia)
•HTG Molecular Diagnostics, Inc. (US)
•Vela Diagnostics (Singapore)
•Amoy Diagnostics Co., Ltd. (China)
•ELITechGroup (France)
•Molbio Diagnostics Pvt. Ltd. (India)
•Savyon Diagnostics (Israel)
•Abacus Diagnostica Oy (Finland)
•geneOmbio Technologies Pvt. Ltd. (India)

Research Coverage:
This report provides a detailed picture of the global molecular diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, test type, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Table of Contents

1INTRODUCTION36
1.1OBJECTIVES OF THE STUDY36
1.2MARKET DEFINITION36
1.2.1INCLUSIONS AND EXCLUSIONS OF THE STUDY37
1.3MARKETS COVERED38
1.3.1MOLECULAR DIAGNOSTICS MARKET38
1.3.2YEARS CONSIDERED FOR THE STUDY39
1.4CURRENCY39
1.5LIMITATIONS39
1.6STAKEHOLDERS40
1.7SUMMARY OF CHANGES40
2RESEARCH METHODOLOGY42
2.1RESEARCH DATA42
2.2RESEARCH APPROACH42
FIGURE 1MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY42
2.2.1SECONDARY DATA43
2.2.1.1Key data from secondary sources43
2.2.2PRIMARY DATA44
2.2.2.1Primary sources45
2.2.2.2Key data from primary sources45
2.2.2.3Key industry insights47
2.2.2.4Breakdown of primary interviews47
FIGURE 2BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS47
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION48
2.3MARKET SIZE ESTIMATION48
2.3.1BOTTOM-UP APPROACH49
2.3.1.1Approach 1: Company revenue estimation approach49
FIGURE 4BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH49
2.3.1.2Approach 2: Presentations of companies and primary interviews49
2.3.1.3Growth forecast50
2.3.1.4CAGR projections50
FIGURE 5CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS50
2.3.2TOP-DOWN APPROACH50
FIGURE 6MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH51
2.4MARKET BREAKDOWN AND DATA TRIANGULATION52
FIGURE 7DATA TRIANGULATION METHODOLOGY52
2.5MARKET SHARE ANALYSIS52
2.6ASSUMPTIONS FOR THE STUDY53
2.7LIMITATIONS53
2.8GROWTH RATE ASSUMPTIONS54
2.9RISK ASSESSMENT54
2.9.1RISK ASSESSMENT: MOLECULAR DIAGNOSTICS MARKET54
3EXECUTIVE SUMMARY55
FIGURE 8MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION)55
FIGURE 9MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,
2022 VS. 2027 (USD MILLION)56
FIGURE 10MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION)56
FIGURE 11MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)57
FIGURE 12MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)58
FIGURE 13MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION)58
4PREMIUM INSIGHTS60
4.1MOLECULAR DIAGNOSTICS MARKET OVERVIEW60
FIGURE 14INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD60
4.2MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 202761
FIGURE 15REAGENTS & KITS WILL CONTINUE TO DOMINATE THE MARKET IN 202661
4.3MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022 VS. 202761
FIGURE 16THE LAB TESTS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 202661
4.4MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 202762
FIGURE 17THE PCR SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING
THE FORECAST PERIOD62
4.5MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 202762
FIGURE 18THE INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 202662
4.6MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022 VS. 202763
FIGURE 19THE DIAGNOSTIC LABORATORIES SEGMENT TO CONTINUE TO DOMINATE
THE MARKET IN 202663
4.7MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES63
FIGURE 20ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD63

5MARKET OVERVIEW64
5.1INTRODUCTION64
5.2MARKET DYNAMICS64
FIGURE 21MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES64
5.2.1DRIVERS65
5.2.1.1Increasing prevalence of infectious diseases and cancer65
TABLE 1ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 202566
TABLE 2GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 202566
5.2.1.2Rising focus on R&D and growing funding in molecular diagnostics67
5.2.1.3Growing awareness of early disease diagnosis in developing countries68
5.2.1.4Rising technological advancements in molecular diagnostics68
5.2.1.5Increasing use of PoC diagnostic tests69
5.2.2RESTRAINTS69
5.2.2.1Unfavorable reimbursement scenario69
5.2.2.2High cost of instruments70
5.2.3OPPORTUNITIES70
5.2.3.1Growing significance of companion diagnostics70
5.2.3.2Growth opportunities in emerging countries70
5.2.4CHALLENGES71
5.2.4.1Changing regulatory landscape71
5.2.4.2Operational barriers71
5.2.4.3Introduction of alternative technologies71
5.2.5IMPACT OF COVID-19 ON THE MOLECULAR DIAGNOSTICS MARKET72
5.3PRICING ANALYSIS73
TABLE 3AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)73
5.4PATENT ANALYSIS74
FIGURE 22LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES74
5.4.1LIST OF MAJOR PATENTS75
5.5VALUE CHAIN ANALYSIS76
FIGURE 23VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES76
5.6SUPPLY CHAIN ANALYSIS77
FIGURE 24MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS77
5.7ECOSYSTEM/MARKET MAP78
FIGURE 25MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP78
5.7.1MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM79
5.8PORTER’S FIVE FORCES ANALYSIS79
TABLE 4MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS79
5.8.1THREAT FROM NEW ENTRANTS80
5.8.2THREAT FROM SUBSTITUTES80
5.8.3BARGAINING POWER OF BUYERS80
5.8.4BARGAINING POWER OF SUPPLIERS80
5.8.5DEGREE OF COMPETITION80
5.9REGULATORY LANDSCAPE81
TABLE 5NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS81
TABLE 6ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS81
TABLE 7LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
TABLE 8REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
5.9.1NORTH AMERICA82
5.9.1.1US82
5.9.1.2Canada82
5.9.2EUROPE83
TABLE 9EUROPE: CLASSIFICATION OF DEVICES83
5.9.3ASIA PACIFIC83
5.9.3.1China83
5.9.3.2Japan83
5.9.3.3India84
5.9.4LATIN AMERICA84
5.9.4.1Brazil84
5.9.4.2Mexico84
5.9.5MIDDLE EAST85
5.9.6AFRICA85
5.10TRADE ANALYSIS85
5.10.1TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS85
5.10.1.1Import data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)85
5.10.1.2Export data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)86
5.11TECHNOLOGY ANALYSIS86
5.12KEY CONFERENCES & EVENTS IN 2022–202387
TABLE 10MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS87
5.13TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES89
5.13.1REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC89
FIGURE 26REVENUE SHIFT IN THE MOLECULAR DIAGNOSTICS MARKET89
5.14KEY STAKEHOLDERS & BUYING CRITERIA90
5.14.1KEY STAKEHOLDERS IN THE BUYING PROCESS, BY END USER90
FIGURE 27INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER90
TABLE 11INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER (%)90
5.14.2BUYING CRITERIA90
FIGURE 28KEY BUYING CRITERIA, BY END USER90
TABLE 12KEY BUYING CRITERIA, BY END USER91
5.15CASE STUDIES91
FIGURE 29CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA91
6MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE92
6.1INTRODUCTION93
TABLE 13MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)93
TABLE 14PRICES OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)93
6.2REAGENTS & KITS94
6.2.1RECURRENT PURCHASES OF REAGENTS & KITS—A KEY FACTOR PROPELLING MARKET GROWTH94
TABLE 15MOLECULAR DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION,
2020–2027 (USD MILLION)95
6.3INSTRUMENTS95
6.3.1INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST THE DEMAND FOR MOLECULAR DIAGNOSTIC INSTRUMENTS95
TABLE 16KEY INSTRUMENTS AVAILABLE IN THE MARKET96
TABLE 17MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION,
2020–2027 (USD MILLION)96
6.4SERVICES & SOFTWARE97
6.4.1GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH IN THIS MARKET SEGMENT97
TABLE 18MOLECULAR DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)97
7MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE98
7.1INTRODUCTION99
TABLE 19MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,
2020–2027 (USD MILLION)99
7.2LAB TESTS99
7.2.1HIGH BURDEN OF COVID-19 TO DRIVE MARKET GROWTH99
TABLE 20MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION,
2020–2027 (USD MILLION)100
7.3POC TESTS100
7.3.1INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENTAL GROWTH IN THE COMING YEARS100
TABLE 21MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION,
2020–2027 (USD MILLION)101

8MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY102
8.1INTRODUCTION103
8.1.1PRIMARY NOTES103
8.1.1.1Key industry insights103
TABLE 22MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)103
8.2POLYMERASE CHAIN REACTION (PCR)104
8.2.1GROWING USE OF PCR IN PROTEOMICS AND GENOMICS MAKES THIS THE LARGEST MARKET SEGMENT104
TABLE 23MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2020–2027 (USD MILLION)105
8.3ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)105
8.3.1COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH105
TABLE 24MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)106
8.4DNA SEQUENCING & NEXT-GENERATION SEQUENCING106
8.4.1INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL GROWTH IN THIS MARKET SEGMENT106
TABLE 25MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)107
8.5IN SITU HYBRIDIZATION (ISH)107
8.5.1RISING PREVALENCE OF CANCER AND GENETIC DISORDERS— A KEY FACTOR DRIVING GROWTH107
TABLE 26MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY REGION, 2020–2027 (USD MILLION)108
8.6DNA MICROARRAYS108
8.6.1INTRODUCTION OF DNA MICROARRAYS HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS108
TABLE 27MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)109
8.7OTHER TECHNOLOGIES109
TABLE 28MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2020–2027 (USD MILLION)110
9MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION111
9.1INTRODUCTION112
TABLE 29MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)112
9.2INFECTIOUS DISEASE DIAGNOSTICS112
TABLE 30MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)113
TABLE 31MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)113
9.2.1COVID-19114
9.2.1.1Growing burden of COVID-19 is a key factor driving market growth114
TABLE 32DISTRIBUTION OF TOTAL NUMBER OF CASES, BY COUNTRY114
TABLE 33MOLECULAR DIAGNOSTICS MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (USD MILLION)115
TABLE 34MOLECULAR DIAGNOSTICS MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (MILLION TESTS)115
9.2.2HEPATITIS115
9.2.2.1Increasing adoption of advanced technologies for the diagnosis of hepatitis B to drive growth in this segment115
TABLE 35MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (USD MILLION)116
TABLE 36MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)116
9.2.3HIV117
9.2.3.1High global prevalence of HIV will drive the need for molecular diagnostic tests117
TABLE 37MOLECULAR DIAGNOSTICS MARKET FOR HIV TESTING, BY REGION,
2020–2027 (USD MILLION)117
TABLE 38MOLECULAR DIAGNOSTICS MARKET FOR HIV TESTING, BY REGION,
2020–2027 (MILLION TESTS)118
9.2.4HAI118
9.2.4.1Rising burden of MRSA infections and the increasing adoption of technologically advanced HAI diagnostic tests will likely drive market growth118
TABLE 39MOLECULAR DIAGNOSTICS MARKET FOR HAI TESTING, BY REGION,
2020–2027 (USD MILLION)119
TABLE 40MOLECULAR DIAGNOSTICS MARKET FOR HAI TESTING, BY REGION,
2020–2027 (MILLION TESTS)119
9.2.5CT/NG119
9.2.5.1CT/NG infections are the most common STDs worldwide—a key factor driving market growth119
TABLE 41MOLECULAR DIAGNOSTICS MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (USD MILLION)120
TABLE 42MOLECULAR DIAGNOSTICS MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (MILLION TESTS)120
9.2.6HPV121
9.2.6.1Technological advancements such as rapid HPV diagnostics drive growth in this segment121
TABLE 43MOLECULAR DIAGNOSTICS MARKET FOR HPV TESTING, BY REGION,
2020–2027 (USD MILLION)121
TABLE 44MOLECULAR DIAGNOSTICS MARKET FOR HPV TESTING, BY REGION,
2020–2027 (MILLION TESTS)121
9.2.7TUBERCULOSIS122
9.2.7.1Increasing burden of TB globally to propel the demand for MDx tests122
TABLE 45MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING,
BY REGION, 2020–2027 (USD MILLION)122
TABLE 46MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING,
BY REGION, 2020–2027 (MILLION TESTS)123

9.2.8INFLUENZA123
9.2.8.1Rising focus on containing the spread of influenza to propel growth in this segment123
TABLE 47MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (USD MILLION)124
TABLE 48MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (MILLION TESTS)124
9.2.9OTHER INFECTIOUS DISEASES124
TABLE 49MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES,
BY REGION, 2020–2027 (USD MILLION)125
9.3ONCOLOGY TESTING125
TABLE 50MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)126
TABLE 51MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)126
9.3.1BREAST CANCER127
9.3.1.1Increasing prevalence of breast cancer is a key driver for market growth127
TABLE 52BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040127
TABLE 53MOLECULAR DIAGNOSTIC MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)127
9.3.2COLORECTAL CANCER128
9.3.2.1Rising focus on the development of companion diagnostic assays for colorectal cancer drives market growth128
TABLE 54MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)128
9.3.3LUNG CANCER129
9.3.3.1Increasing research for lung cancer biomarkers to drive market growth129
TABLE 55MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION,
2020–2027 (USD MILLION)129
9.3.4PROSTATE CANCER129
9.3.4.1Advancements in genomic technologies for the development of new biomarkers will drive the market growth129
TABLE 56MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)130
9.3.5OTHER CANCERS130
TABLE 57GLOBAL CANCER INCIDENCE, 2020130
TABLE 58MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)131
9.4GENETIC TESTING131
9.4.1GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES—A KEY FACTOR DRIVING MARKET GROWTH131
TABLE 59MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)131
9.5OTHER APPLICATIONS132
TABLE 60MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)132
10MOLECULAR DIAGNOSTICS MARKET, BY END USER133
10.1INTRODUCTION134
TABLE 61MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)134
10.2DIAGNOSTIC LABORATORIES134
10.2.1INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO DRIVE MARKET GROWTH134
TABLE 62MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2020–2027 (USD MILLION)135
10.3HOSPITALS & CLINICS135
10.3.1INCREASING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS TO DRIVE THE GROWTH OF THIS SEGMENT135
TABLE 63MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)136
10.4OTHER END USERS136
TABLE 64MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)137
11MOLECULAR DIAGNOSTICS MARKET, BY REGION138
11.1INTRODUCTION139
TABLE 65MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2020–2027 (USD MILLION)139
11.2NORTH AMERICA140
FIGURE 30NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT141
TABLE 66NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)142
TABLE 67NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)142
TABLE 68NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)143
TABLE 69NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)143
TABLE 70NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)144
TABLE 71NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)144
TABLE 72NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)145
11.2.1US145
11.2.1.1Increasing prevalence of infectious diseases and cancer to drive market growth in the US145
TABLE 73US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)146
TABLE 74US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)146
TABLE 75US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)147
TABLE 76US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)147
TABLE 77US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)148
TABLE 78US: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)148
11.2.2CANADA148
11.2.2.1Availability of funding for genomics research makes Canada a sizeable market for molecular diagnostics148
TABLE 79CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)149
TABLE 80CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)150
TABLE 81CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)150
TABLE 82CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)151
TABLE 83CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)151
TABLE 84CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)152
11.3EUROPE152
TABLE 85EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)153
TABLE 86EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)153
TABLE 87EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)154
TABLE 88EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)154
TABLE 89EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)155
TABLE 90EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)155
TABLE 91EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)156
11.3.1GERMANY156
11.3.1.1Increasing healthcare expenditure to drive market growth in Germany156
TABLE 92GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)157
TABLE 93GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)157
TABLE 94GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)158
TABLE 95GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)158
TABLE 96GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)159
TABLE 97GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)159
11.3.2UK159
11.3.2.1Growing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK159
TABLE 98UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)160
TABLE 99UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)160
TABLE 100UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)161
TABLE 101UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)161
TABLE 102UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)162
TABLE 103UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)162
11.3.3FRANCE162
11.3.3.1Rising R&D expenditure in France to drive market growth162
TABLE 104FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)163
TABLE 105FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)163
TABLE 106FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)164
TABLE 107FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)164
TABLE 108FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)165
TABLE 109FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)165
11.3.4ITALY165
11.3.4.1Adoption of advanced diagnostic technologies to drive market growth in Italy165
TABLE 110ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)166
TABLE 111ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)166
TABLE 112ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)167
TABLE 113ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)167
TABLE 114ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)168
TABLE 115ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)168
11.3.5RUSSIA168
11.3.5.1Increasing access to quality healthcare will support market growth in Russia168
TABLE 116RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)169
TABLE 117RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)169
TABLE 118RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)170
TABLE 119RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)170
TABLE 120RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)171
TABLE 121RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)171
11.3.6SPAIN171
11.3.6.1Growing demand for genetic testing in Spain to create major growth opportunities for market players171
TABLE 122SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)172
TABLE 123SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)172
TABLE 124SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)173
TABLE 125SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)173
TABLE 126SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)174
TABLE 127SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)174
11.3.7REST OF EUROPE174
TABLE 128ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)175
TABLE 129ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)175
TABLE 130ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)175
TABLE 131ROE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)176
TABLE 132ROE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)176
TABLE 133ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)177
11.4ASIA PACIFIC177
FIGURE 31APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT178
TABLE 134APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)179
TABLE 135APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)179
TABLE 136APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)180
TABLE 137APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)180
TABLE 138APAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)181
TABLE 139APAC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)181
TABLE 140APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)182
11.4.1CHINA182
11.4.1.1Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth182
TABLE 141CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)183
TABLE 142CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)183
TABLE 143CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)184
TABLE 144CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)184
TABLE 145CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)185
TABLE 146CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)185
11.4.2JAPAN185
11.4.2.1Universal healthcare reimbursement policy to drive market growth in Japan185
TABLE 147JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)186
TABLE 148JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)186
TABLE 149JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)187
TABLE 150JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)187
TABLE 151JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)188
TABLE 152JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)188
11.4.3INDIA188
11.4.3.1Increasing private & public investments in the country’s healthcare system will drive market growth188
TABLE 153INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)189
TABLE 154INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)190
TABLE 155INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)190
TABLE 156INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)191
TABLE 157INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)191
TABLE 158INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)192
11.4.4AUSTRALIA192
11.4.4.1High prevalence of infectious diseases makes Australia a relatively large market in the APAC192
TABLE 159AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)192
TABLE 160AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)193
TABLE 161AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)193
TABLE 162AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)194
TABLE 163AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)194
TABLE 164AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)195
11.4.5REST OF ASIA PACIFIC195
TABLE 165ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)196
TABLE 166ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)196
TABLE 167ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)197
TABLE 168ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)197
TABLE 169ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)198
TABLE 170ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)198
11.5LATIN AMERICA199
TABLE 171LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)199
TABLE 172LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)199
TABLE 173LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)200
TABLE 174LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)200
TABLE 175LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)201
TABLE 176LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)201
TABLE 177LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)202
11.5.1BRAZIL202
11.5.1.1Improving healthcare infrastructure to drive the growth of
the molecular diagnostics market in Brazil202
TABLE 178BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)203
TABLE 179BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)203
TABLE 180BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)204
TABLE 181BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)204
TABLE 182BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)205
TABLE 183BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)205
11.5.2MEXICO205
11.5.2.1Improving accessibility and affordability of healthcare services in Mexico makes it a favorable market for molecular diagnostics205
TABLE 184MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)206
TABLE 185MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)206
TABLE 186MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)207
TABLE 187MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)207
TABLE 188MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING,
BY TYPE, 2020–2027 (USD MILLION)208
TABLE 189MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)208
11.5.3REST OF LATIN AMERICA208
TABLE 190ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)209
TABLE 191ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)209
TABLE 192ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)210
TABLE 193ROLATAM: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)210
TABLE 194ROLATAM: MOLECULAR DI

Report Title: Molecular Diagnostics Market by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline